Home

Download

Statistics

Landscape

Help

Contact

	Dataset summary
	Drug summary
	Umap of single cell types and conditions (resistant and sensitive)
	Comparison of cell composition between the resistant and sensitive groups (This dataset does not contain this module)
	Comparison of intra-tumor heterogeneity (ITH) and epithelial-mesenchymal transition (EMT) scores of malignant cells between the resistant and sensitive groups
	Difference of cell-cell interactions between the resistant and sensitive groups
	Differentially expressed genes (DEGs) between the resistant and sensitive groups for each cell type
	Mechanism analysis of drug resistance-related DEGs for each cell type in the pre-treatment samples (This dataset does not contain this module)
	Mechanism analysis of drug resistance-related DEGs for each cell type in the post-treatment samples
	Mechanism analysis of drug resistance-related DEGs for each cell type in one patient or cell lines (This dataset does not contain this module)
	MicroRNAs (miRNAs) regulating drug resistance-related DEGs for Malignant cells
	Motifs and transcription factors (TFs) regulating drug resistance-related DEGs for each cell type
•	Differentially expressed genes act as transcription factors

Dataset: GSE207422_Sin

Dataset summary for GSE207422_Sin

Datast information	Dataset	GSE207422_Sin
	PMID	36869384
	Raw data ID/link	https://ngdc.cncb.ac.cn/gsa-human/browse/HRA001033
	Organism	Homo sapiens
	Source	patients
	Tissue	Tumor tissue
	Cancer type level1	Lung cancer
	Cancer type level2	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)
	Regimen	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)
	Drug type	Immunotherapy
	Sample size	post (resistant 5, sensitive 2)
	Cell number	22187
	Extract protocol	BD Rhapsody system
	Data processing	BD Rhapsody Whole Transcriptome Analysis (WTA) Pipeline
	Public date	Public on Mar 21, 2023
	Description	This dataset has 7 patients with post-treatment samples.

Top

Drug summary for GSE207422_Sin

Drug name	DrugBank ID	Drug type	Targets name	Targets uniprot ID
"Sintilimab"	DB15765	biotech	PDCD1	Q15116
"carboplatin" is not included in the drug list.
"Docetaxel"	DB01248	small molecule	TUBB1; MAP2; MAP4; MAPT; BCL2; NR1I2	Q9H4B7; P11137; P27816; P10636; P10415; O75469
"Pemetrexed"	DB00642	small molecule	TYMS; ATIC; DHFR; GART	P04818; P31939; P00374; P22102
"emcitabine" is not included in the drug list.

Top

Umap of single cell types and conditions (resistant and sensitive)

Umap of cell types and conditions (resistant and sensitive). If this dataset has both pre-treatment and post-treatment samples, the cell types were annotated together. If this dataset is a cell line dataset, the UMAP of cell clusters and the cell ratio of drug-resistant and sensitive groups within each cluster will also be shown. (If the image exists, the user can click on it to enlarge it in a new window.)

Umap of cell types

Umap of conditions

Top

Comparison of cell composition between the resistant and sensitive groups

In the pre-treatment samples, the cell composition of the resistant and sensitive groups were compared.
* represents significant difference. (If the image exists, the user can click on it to enlarge it in a new window.)

In the post-treatment samples, the cell composition of the resistant and sensitive groups were compared.
* represents significant difference. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Comparison of ITH and EMT scores of malignant cells between the resistant and sensitive groups

Comparison of ITH (intra-tumoral heterogeneity) and EMT (epithelial-mesenchymal transition) scores of malignant cells between the resistant and sensitive groups. ITH represents intratumoral heterogeneity, EMT represents epithelial mesenchymal transition, pre represents pre-treatment, post represents post-treatment, post2 represents longer post-treatment. (If the image exists, the user can click on it to enlarge it in a new window.)

Comparison of ITH scores

Comparison of EMT scores

Top

Difference of cell-cell interactions between the resistant and sensitive groups

In the pre-treatment samples, the difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

In the post-treatment samples, the difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

resistant vs. sensitive

Dot plot of significant ligand-receptor pairs in the resistant group	Dot plot of significant ligand-receptor pairs in the sensitive group

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Top

Differentially expressed genes (DEGs) between the resistant and sensitive groups for each cell type

In the pre-treatment samples, the differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

In the post-treatment samples, the differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

Gene symbol	Gene id	avg_log2FC	p_val	p_val_adj	pct.1	pct.2	Cell type	Timepoint
FCGR3B	ENSG00000162747	-0.79263	0.00e+00	0.00e+00	0.909	0.985	Neutrophils	post
JAML	ENSG00000160593	-0.80368	0.00e+00	0.00e+00	0.284	0.673	Neutrophils	post
MYADM	ENSG00000179820	-0.817641	0.00e+00	0.00e+00	0.334	0.667	Neutrophils	post
LYZ	ENSG00000090382	-0.921751	0.00e+00	2.15e-42	0.352	0.645	Neutrophils	post
IER2	ENSG00000160888	-0.966707	0.00e+00	0.00e+00	0.542	0.86	Neutrophils	post
BTG2	ENSG00000159388	-1.01399	0.00e+00	0.00e+00	0.708	0.915	Neutrophils	post
PROK2	ENSG00000163421	-1.05064	1.51e-36	3.62e-32	0.177	0.393	Neutrophils	post
SCGB1A1	ENSG00000149021	-1.1409	0.00e+00	0.00e+00	0.059	0.537	Neutrophils	post
NCOA4	ENSG00000266412	-1.14435	0.00e+00	0.00e+00	0.259	0.709	Neutrophils	post
C5AR1	ENSG00000197405	-1.20587	0.00e+00	0.00e+00	0.716	0.936	Neutrophils	post
RHOB	ENSG00000143878	-1.25153	0.00e+00	0.00e+00	0.311	0.675	Neutrophils	post
MNDA	ENSG00000163563	-1.32414	0.00e+00	0.00e+00	0.653	0.943	Neutrophils	post
KLF2	ENSG00000127528	-1.32822	0.00e+00	0.00e+00	0.452	0.866	Neutrophils	post
RGS2	ENSG00000116741	-1.34117	0.00e+00	0.00e+00	0.692	0.958	Neutrophils	post
PTGS2	ENSG00000073756	-1.8188	0.00e+00	0.00e+00	0.275	0.752	Neutrophils	post
SPP1	ENSG00000118785	2.84957	5.04e-10	1.21e-05	0.306	0.082	Mono/Macro	post
CTSL	ENSG00000135047	1.94257	3.86e-40	9.28e-36	0.895	0.61	Mono/Macro	post
CTSB	ENSG00000285132	1.5815	0.00e+00	0.00e+00	0.997	0.943	Mono/Macro	post
SDS	ENSG00000135094	1.55955	1.48e-29	3.54e-25	0.531	0.057	Mono/Macro	post
CD163	ENSG00000177575	1.54946	0.00e+00	0.00e+00	0.866	0.39	Mono/Macro	post
LGMN	ENSG00000100600	1.44791	2.02e-28	4.86e-24	0.686	0.283	Mono/Macro	post
GLUL	ENSG00000135821	1.41977	0.00e+00	0.00e+00	0.972	0.849	Mono/Macro	post
TMEM176B	ENSG00000106565	1.3999	2.19e-40	5.26e-36	0.832	0.447	Mono/Macro	post
CCL2	ENSG00000108691	1.29532	1.95e-10	4.68e-06	0.342	0.094	Mono/Macro	post
HIF1A	ENSG00000100644	1.2364	4.84e-32	1.16e-27	0.708	0.277	Mono/Macro	post
SOD2	ENSG00000291237	1.21794	8.50e-24	2.04e-19	0.764	0.472	Mono/Macro	post
SAT1	ENSG00000130066	1.15804	1.26e-44	2.87e-40	0.984	0.805	Mono/Macro	post
TMEM176A	ENSG00000002933	1.14342	7.32e-35	1.76e-30	0.755	0.314	Mono/Macro	post
PLIN2	ENSG00000147872	1.13642	3.89e-20	9.34e-16	0.81	0.541	Mono/Macro	post
RNASE1	ENSG00000129538	1.13447	1.43e-08	3.43e-04	0.277	0.075	Mono/Macro	post
HAMP	ENSG00000105697	1.1224	3.51e-13	8.42e-09	0.322	0.05	Mono/Macro	post
PLTP	ENSG00000100979	1.10867	2.52e-19	6.06e-15	0.533	0.17	Mono/Macro	post
MT2A	ENSG00000125148	1.09327	3.00e-12	7.21e-08	0.593	0.327	Mono/Macro	post
LILRB4	ENSG00000278555	1.04028	4.21e-38	1.01e-33	0.753	0.264	Mono/Macro	post
IFI6	ENSG00000126709	1.03825	6.90e-21	1.66e-16	0.871	0.642	Mono/Macro	post
PFKFB3	ENSG00000170525	1.03156	4.58e-30	1.10e-25	0.57	0.088	Mono/Macro	post
IFITM3	ENSG00000142089	0.995416	2.16e-27	5.19e-23	0.768	0.371	Mono/Macro	post
ADM	ENSG00000148926	0.982551	2.08e-19	5.00e-15	0.414	0.05	Mono/Macro	post
TIMP1	ENSG00000102265	0.949088	4.33e-13	1.04e-08	0.517	0.214	Mono/Macro	post
PSAP	ENSG00000197746	0.931595	2.16e-40	5.20e-36	0.997	0.956	Mono/Macro	post
PLAUR	ENSG00000011422	0.904014	3.56e-18	8.55e-14	0.841	0.629	Mono/Macro	post
VEGFA	ENSG00000112715	0.902864	1.31e-22	3.15e-18	0.511	0.088	Mono/Macro	post
CALR	ENSG00000179218	0.897757	7.62e-29	1.83e-24	0.948	0.755	Mono/Macro	post
IER3	ENSG00000235030	0.892024	1.40e-13	3.37e-09	0.635	0.327	Mono/Macro	post
ZFP36L1	ENSG00000185650	0.866687	1.89e-17	4.54e-13	0.793	0.503	Mono/Macro	post
G0S2	ENSG00000123689	0.859013	2.04e-06	4.91e-02	0.337	0.157	Mono/Macro	post
DDIT4	ENSG00000168209	0.85706	8.66e-18	2.08e-13	0.4	0.057	Mono/Macro	post
ARL4C	ENSG00000188042	0.846879	2.23e-17	5.36e-13	0.564	0.226	Mono/Macro	post
BASP1	ENSG00000176788	0.836794	1.04e-21	2.51e-17	0.669	0.314	Mono/Macro	post
CREG1	ENSG00000143162	0.834638	1.05e-25	2.51e-21	0.849	0.673	Mono/Macro	post

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The following are differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in the pre-treatment samples

Enrichment results for 5 known drug-resistant mechanisms in malignant cells and 1 known mechanism in TME cells.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group of pre-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group of pre-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window.Complete files can be downloaded from the download section.)

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in the post-treatment samples

Enrichment results for 5 known drug resistance mechanisms in malignant cells and 1 known mechanism in TME cells.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Enrichment results for 5 known drug resistance mechanisms in malignant cells

Mechnism	Pval	FDR	Signature	Geneset	Overlap	Background	Cell type	Enriched Genes
Unusual Activation of Pro-survival Pathway	1.10e-03	5.30e-03	199	781	16	23467	Malignant cells	CDKN1A,GSTP1,SLC2A1,HSPA1A,ID1,YWHAZ,FOXA1,GAPDH,LDHA,LRIG1,NOTCH3,NQO1,RAC1,UCP2,ENO1,ALDH1A1
Drug Inactivation by Structure Modification	2.10e-01	4.50e-01	199	27	1	23467	Malignant cells	GSTP1
Irregularity in Drug Uptake and Drug Efflux	2.70e-01	4.50e-01	199	37	1	23467	Malignant cells	SLC2A1
Epigenetic Alteration of DNA, RNA or Protein	9.80e-01	1.00e+00	199	455	1	23467	Malignant cells	GAPDH
Aberration of the Drug's Therapeutic Target	1.00e+00	1.00e+00	199	90	0	23467	Malignant cells

Enrichment results for 1 known drug resistance mechanisms in TME cells

Mechnism	Pval	FDR	Signature	Geneset	Overlap	Background	Cell type	Enriched Genes
Regulation by the Disease Microenvironment	3.90e-01	3.90e-01	168	186	2	23467	B cells	TP53INP1,CXCR4
Regulation by the Disease Microenvironment	2.00e-01	2.00e-01	194	186	3	23467	CD4+ T cells	CXCR4,FYN,SOCS3
Regulation by the Disease Microenvironment	3.00e-01	3.00e-01	349	186	4	23467	CD8+ T cells	CXCR4,RHOB,SOCS3,MALAT1
Regulation by the Disease Microenvironment	1.00e+00	1.00e+00	7	186	0	23467	Fibroblasts	NA
Regulation by the Disease Microenvironment	1.00e+00	1.00e+00	41	186	0	23467	Mast cells	NA
Regulation by the Disease Microenvironment	3.00e-01	3.00e-01	456	186	5	23467	Mono_Macro	VEGFA,CXCR4,SOCS3,VIM,FBP1
Regulation by the Disease Microenvironment	3.50e-01	3.50e-01	266	186	3	23467	Neutrophils	PAK1,CXCR4,RHOB
Regulation by the Disease Microenvironment	1.90e-02	1.90e-02	27	186	2	23467	NK cells	CX3CR1,CXCR4
Regulation by the Disease Microenvironment	9.20e-02	9.20e-02	64	186	2	23467	pDCs	CX3CR1,CXCR4
Regulation by the Disease Microenvironment	1.00e+00	1.00e+00	58	186	0	23467	Plasma cells	NA

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group of post-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Up-regulated Hallmark	Up-regulated KEGG	Up-regulated GO BP

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group of post-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Down-regulated Hallmark	Down-regulated KEGG	Down-regulated GO BP
There is no signaficant down-regulated pathways in resistant group

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in one patient or cell lines

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. Enrichment results for 5 known drug resistance mechanisms in malignant cells and 1 known mechanism in TME cells are shown here.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Top

MicroRNAs (miRNAs) regulating drug resistance-related DEGs for malignant cells

In the pre-treatment samples, the miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for malignant cells are shown here. If the gene does not have any miRNAs with a score greater than 80, it will not be shown. Here only the names of miRNAs with a score greater than 90 are shown, but some names will not be shown because of too many overlaps. (Complete files containing all datasets and cell types can be downloaded from the download section.)

In the post-treatment samples, the miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for Malignant cells are shown here. If the gene does not have any miRNAs with a score greater than 80, it will not be shown. Here only the names of miRNAs with a score greater than 90 are shown, but some names will not be shown because of too many overlaps. (Complete files containing all datasets and cell types can be downloaded from the download section.)

Regulating up-regulated DEGs in resistant group	Regulating down-regulated DEGs in resistant group

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for Malignant cells are shown here. Here only the names of miRNAs with a score greater than 80 are shown, but some names will not be shown because of too many overlaps. If the gene does not have any miRNAs with a score greater than 90, it will not be shown. (Complete files containing all datasets and cell types can be downloaded from the download section.)

Top

Motifs and transcription factors (TFs) regulating drug resistance-related DEGs for each cell type

In the pre-treatment samples, the motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

In the post-treatment samples, the motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

Motifs and TFs regulating up-regulated DEGs in resistant group of the post-treatment samples

motif	motif	NES	AUC	TF_highConf	Cell_type
	hocomoco__TYY2_HUMAN.H11MO.0.D	4.86	0.0798	YY2 (directAnnotation).	B cells
	transfac_pro__M02080	4.55	0.0762	ISL2 (directAnnotation).	B cells
	metacluster_141.2	4.33	0.0737	E2F2; E2F3 (directAnnotation).	B cells
	transfac_pro__M06500	4.19	0.0722	ZNF614 (directAnnotation).	B cells
	taipale_tf_pairs__ETV2_HES7_RSCGGAANNNNNNNCACGTGNN_CAP_repr	4.18	0.072	ETV2; HES7 (directAnnotation).	B cells
	transfac_pro__M06301	4.06	0.0706	ZNF404 (directAnnotation).	B cells
	taipale__YY2_DBD_NNCCGCCATNW_repr	3.85	0.0683	YY2 (directAnnotation).	B cells
	taipale_tf_pairs__ELK1_TEF_NSCGGAWNTTACGTAAN_CAP	3.73	0.0669	ELK1; TEF (directAnnotation).	B cells
	tfdimers__MD00032	3.66	0.0661	GFI1; GFI1B; NKX3-2 (directAnnotation).	B cells
	taipale_cyt_meth__JUND_NRTGACGCATN_eDBD_repr	3.64	0.0658	JUND (directAnnotation).	B cells

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43

Motifs and TFs regulating down-regulated DEGs in resistant group of the post-treatment samples

motif	motif	NES	AUC	TF_highConf	Cell_type
	transfac_pro__M05731	5.27	0.232	ZNF660 (directAnnotation).	B cells
	transfac_pro__M06037	4.57	0.206	ZNF197 (directAnnotation).	B cells
	metacluster_103.2	4.48	0.203	ZNF136; ZNF680 (directAnnotation).	B cells
	transfac_pro__M05542	4.29	0.196	SNAPC4 (directAnnotation).	B cells
	transfac_pro__M06539	4.18	0.192	ZNF483 (directAnnotation).	B cells
	metacluster_52.13	3.94	0.183	LEF1; LEF1; LEF1; LEF1; TCF7; TCF7; TCF7L1; TCF7L1 (directAnnotation).	B cells
	tfdimers__MD00375	3.82	0.179	KLF4; PITX3 (directAnnotation).	B cells
	transfac_pro__M06661	3.82	0.179	ZNF426 (directAnnotation).	B cells
	transfac_pro__M05821	3.49	0.167	ZNF880 (directAnnotation).	B cells
	taipale__ZNF524_full_ACCCTTGAACCC_repr	3.47	0.166	ZNF524 (directAnnotation).	B cells

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. Motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

Top

Differentially expressed genes act as transcription factors

This table shows the differentially expressed genes that act as transcription factors. (Complete files can be downloaded from the download section.)

TF	motif	Expression	Cell type	Timepoint
KLF2	metacluster_163.1	up	B cells	post
KLF2	metacluster_170.2	up	B cells	post
CREM	transfac_pro__M00801	up	CD4+ T cells	post
IKZF2	tfdimers__MD00029	up	CD4+ T cells	post
TCF7	metacluster_52.13	down	CD4+ T cells	post
JUND	taipale_cyt_meth__JUND_NRTGACGCATN_eDBD_repr	up	CD8+ T cells	post
PRDM1	metacluster_2.9	up	CD8+ T cells	post
FOXP1	hocomoco__FOXP1_HUMAN.H11MO.0.A	down	Mast cells	post
CEBPD	taipale_tf_pairs__ETV2_CEBPD_RSCGGANNTTGCGYAAN_CAP_repr	up	Mono/Macro	post
FOSL2	metacluster_157.2	up	Mono/Macro	post

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."